SPRY
ARSBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that neffy keeps compounding from a $22.7M Q1, payer access keeps widening (Florida Medicaid now covered, CVS Caremark pending), and the expanded 148-rep sales force plus cash runway through break-even support continued launch investment.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
CSU data is not due until Q4 2026, so pipeline optionality is back-end loaded.
Momentum
29
Value
43
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $32.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $28.33
Why
Momentum29 · Δ7d +9.5
Value43 · Δ7d +0.0
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
29
34% active weight
Current posture
7d trendImproving
Δ7d
+9.5
Δ21d
+6.1
Value
43
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade B. Momentum 29.0 / Value 43.0 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$936.43M
Beta
0.79
Shares Out
98.85M
P/E (TTM) · Derived
118.4
P/S (TTM)
7.60
P/FCF (TTM)
83.51
Rev YoY
+1471.6%
EPS YoY
-162.6%
Gross Margin
+89.4%
Op Margin
-63.6%
Net Debt
-
Current Ratio
6.66
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology